200 related articles for article (PubMed ID: 1614274)
21. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Waldmeier PC; Delini-Stula A; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
23. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
Waldmeier PC; Baumann PA
Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533
[TBL] [Abstract][Full Text] [Related]
24. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
Fagervall I; Ross SB
J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795
[TBL] [Abstract][Full Text] [Related]
25. Reciprocal changes in striatal dopamine and beta-phenylethylamine induced by reserpine in the presence of monoamine oxidase inhibitors.
Juorio AV; Greenshaw AJ; Wishart TB
Naunyn Schmiedebergs Arch Pharmacol; 1988 Dec; 338(6):644-8. PubMed ID: 3149722
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition by amiflamine of monoamine oxidase type A in rat brain, liver and duodenum.
Ask AL
Naunyn Schmiedebergs Arch Pharmacol; 1984 Aug; 327(1):56-63. PubMed ID: 6493351
[TBL] [Abstract][Full Text] [Related]
27. In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.
Bel N; Artigas F
Naunyn Schmiedebergs Arch Pharmacol; 1995 May; 351(5):475-82. PubMed ID: 7543977
[TBL] [Abstract][Full Text] [Related]
28. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
Waldmeier PC; Stöcklin K
Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
Finberg JP
Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
[TBL] [Abstract][Full Text] [Related]
30. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
Bieck PR
Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
[TBL] [Abstract][Full Text] [Related]
31. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
[TBL] [Abstract][Full Text] [Related]
32. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
Alemany R; Olmos G; García-Sevilla JA
Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
[TBL] [Abstract][Full Text] [Related]
33. Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition.
Schoepp DD; Azzaro AJ
J Neurochem; 1981 Aug; 37(2):527-30. PubMed ID: 6790675
[TBL] [Abstract][Full Text] [Related]
34. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.
Finberg JP; Tenne M
Br J Pharmacol; 1982 Sep; 77(1):13-21. PubMed ID: 6127132
[TBL] [Abstract][Full Text] [Related]
35. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
[TBL] [Abstract][Full Text] [Related]
36. Influence of substrate in the inhibition of rat liver and brain monoamine oxidase.
Fuller RW
Arch Int Pharmacodyn Ther; 1968 Jul; 174(1):32-7. PubMed ID: 4386711
[No Abstract] [Full Text] [Related]
37. [Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver].
Deverina IS
Biokhimiia; 1980 Oct; 45(10):1897-908. PubMed ID: 6786369
[TBL] [Abstract][Full Text] [Related]
38. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
Severina IS; Klimova GI; Nersisian AA
Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482
[TBL] [Abstract][Full Text] [Related]
39. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Ilani T; Lamensdorf I; Finberg JP
Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
[TBL] [Abstract][Full Text] [Related]
40. Drug-induced changes in the formation, storage and metabolism of tyramine in the mouse.
Juorio AV
Br J Pharmacol; 1979 Jul; 66(3):377-84. PubMed ID: 43172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
